Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배윤수 | * |
dc.contributor.author | 이화정 | * |
dc.contributor.author | 이재옥 | * |
dc.date.accessioned | 2019-11-05T16:30:09Z | - |
dc.date.available | 2019-11-05T16:30:09Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 1999-4923 | * |
dc.identifier.other | OAK-25604 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251744 | - |
dc.description.abstract | In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide (DMSO)-based and diazepam injection-based formulations were used to dissolve the compound. In the latter formulation applicable to humans, the changes in PK parameters were monitored at two different concentrations (1 mg/mL and 2 mg/mL). The area under the plasma concentration-time curve from zero time to infinity (AUC(inf)) of Ewha-18278 was highest in the DMSO-based formulation (2 mg/mL). Also, the concentration was increased 1.6-fold at the low concentration of the diazepam injection-based formulation compared to the high concentration. There was no statistical significance in the AUC(inf) of the compound between DMSO-based formulation (2 mg/mL) and diazepam injection-based formulation (1 mg/mL). These results suggest that Ewha-18278 can be delivered to humans by both IV and oral routes. In addition, the diazepam injection-based formulation of Ewha-18278 appears to be a suitable candidate for dosage development for future toxicity test and clinical trial. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | pharmacokinetics | * |
dc.subject | human applicable formulation | * |
dc.subject | pyrazole derivative | * |
dc.subject | NOX1 | * |
dc.subject | 2 | * |
dc.subject | 4 inhibitor | * |
dc.subject | osteoporosis | * |
dc.title | Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative | * |
dc.type | Article | * |
dc.relation.issue | 9 | * |
dc.relation.volume | 11 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | PHARMACEUTICS | * |
dc.identifier.doi | 10.3390/pharmaceutics11090482 | * |
dc.identifier.wosid | WOS:000489151700036 | * |
dc.author.google | Lee, Seul Gee | * |
dc.author.google | Lee, Jaeok | * |
dc.author.google | Kim, Kyung Min | * |
dc.author.google | Lee, Kee-In | * |
dc.author.google | Bae, Yun Soo | * |
dc.author.google | Lee, Hwa Jeong | * |
dc.contributor.scopusid | 배윤수(15031067200) | * |
dc.contributor.scopusid | 이화정(57102029300) | * |
dc.contributor.scopusid | 이재옥(57199423901) | * |
dc.date.modifydate | 20240415133331 | * |